Analytical Data
-
Gene name
PSMD4
- Application
-
Alternative Names
ASF; AF-1; AF; MCB1; Rpn10; S5A; pUB-R5; Antisecretory factor 1; Multiubiquitin chain-binding protein; 26S proteasome regulatory subunit RPN10
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P55036
-
Expression Region
Met1~Lys377
-
Molecular Weight
71kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSMD4 (Proteasome 26S Subunit, Non-ATPase 4) is a crucial component of the 26S proteasome, a multifaceted proteolytic complex responsible for degrading ubiquitinated proteins in eukaryotic cells. Research into PSMD4 has gained traction due to its essential role in regulating various cellular processes, such as the cell cycle, apoptosis, and stress responses. Erroneous regulation of proteasomal degradation pathways, in which PSMD4 is involved, has been implicated in various diseases, including cancer, neurodegenerative disorders, and inflammatory conditions. Studies have shown that PSMD4 interaction with other proteasome subunits is vital for the stability and functionality of the proteasome complex, influencing the degradation rates of key regulatory proteins. Furthermore, PSMD4 has emerged as a potential therapeutic target, with inhibitors being explored for their efficacy in restoring proteasomal function in pathological conditions. The recombinant expression of PSMD4 allows for detailed functional studies, structural analysis, and the exploration of its interactions, thus providing insights into its biological significance and potential as a biomarker or therapeutic target. As the understanding of PSMD4 continues to evolve, its study offers promising avenues for therapeutic intervention in diseases linked to proteasome dysregulation.
